SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Nephrology Referral — Emily Dickinson

PatientEmily Dickinson
Date of birth1971-12-10
IdentifiersMRN HR-NI023-SYN; SSN (made up) 000-23-6081
Document date2026-01-12
AuthorLucinda Hartwell, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Referral

Stage G3a A2 chronic kidney disease with hypertension in a 54-year-old woman without diabetes. Please confirm the probable cause, advise whether further tests are needed, and advise on kidney-protective treatment and follow-up. [S]

Urgency: Routine, within four weeks; please see her on the same morning as her kidney ultrasound, since she travels with difficulty. [S]

Questions for the consultant:

History of Present Illness

Several months of morning headaches, nausea, and tiredness. Blood pressure 166/98 mmHg at today's home visit; she has never been treated for hypertension. She has taken over-the-counter naproxen several times a week for the headaches, stopped today. An urgent care visit fourteen months ago recorded an eGFR of 58 and a urine albumin-creatinine ratio of 190 mg/g, which were not followed up. Today: creatinine 1.20 mg/dL (eGFR 54), potassium 4.4 mmol/L, urine albumin-creatinine ratio 240 mg/g, urine red cells 1 per high-power field, hemoglobin 12.3 g/dL, calcium 9.3 and phosphate 3.8 mg/dL, PTH 74 pg/mL, 25-hydroxyvitamin D 21 ng/mL, HbA1c 5.5 percent, LDL 134 mg/dL. KFRE 0.5 percent at 2 years and 1.6 percent at 5 years. ECG shows borderline voltage for left ventricular hypertrophy. Started today: losartan 50 mg, atorvastatin 20 mg, vitamin D3 1,000 units, and acetaminophen as needed. Never smoker; no alcohol. She has long wished to stay at home and asks for as few clinic trips as possible; video follow-up suits her [S]

Historical basis. These claims are historical evidence, not findings from a modern examination.

1 later historical claim is omitted because it describes events after the index age. See the teaching note.

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Naproxen sodium 220 mg oral tablet, two tablets by mouth as needed for headache (over the counter)Two tablets as needed, up to twice a dayOral route2025-10-01 to 2026-01-12stoppedS
Losartan 50 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-01-12 to 2026-02-02completedS
Atorvastatin 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-01-12activeS
Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-01-12activeS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a dayTwo tablets every 6 hours as needed; maximum 6 tablets a dayOral route2026-01-12activeS

Problems

ProblemClinical statusVerificationCodeProvenance
Chronic kidney disease stage G3a A2, attributed to hypertension; synthetic modern diagnosis linked to the Bright's disease entered on her death certificateactiveconfirmed N18.31S — Synthetic modern diagnosis. Bright's disease as her recorded cause of death is documented (D); what it meant in her case is a retrospective question (R), and no kidney test from her lifetime exists.
Hypertension with chronic kidney disease (hypertensive chronic kidney disease, stage 3a); synthetic modern diagnosis linked to the retrospective view that she had severe hypertensionactiveconfirmed I12.9S — Synthetic modern diagnosis; severe hypertension is a retrospective interpretation (R, possible), and no blood pressure from her lifetime exists.
Vitamin D deficiency with a mildly raised PTH in chronic kidney diseaseactiveconfirmed E55.9S — Synthetic laboratory finding at the intake visit.

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
Late winter of 1848Lung congestion and cough; removed from her seminary for about a monthD (CLM-0002)
1851Symptoms then thought to be consumptive, treated with a glycerine prescription for about two years until they subsided; no tuberculosis diagnosis is documentedD (CLM-0003)
1863 to 1865Eye affliction with sensitivity to light and aching eyes, treated by a Boston ophthalmologist with dim light and no reading during two long stays in Cambridgeport; apparently cured. The diagnosis is not recorded (iritis most often proposed)R (CLM-0004, CLM-0005, CLM-0006)
October 1883Nervous prostration after a death in her family, followed by continuing ill healthD (CLM-0010)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-01-12Body height163cmS
2026-01-12Body weight54kgS
2026-01-12Body mass index (BMI) [Ratio]20.3kg/m2S
2026-01-12Systolic blood pressure166mm[Hg]S
2026-01-12Diastolic blood pressure98mm[Hg]S
2026-01-12Heart rate78/minS
2026-01-12Respiratory rate14/minS
2026-01-12Body temperature36.6CelS
2026-01-12Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-01-12Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-01-12Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
2026-01-12Carbon dioxide, total [Moles/volume] in Serum or Plasma24mmol/L22-29 mmol/LNormalS
2026-01-12Urea nitrogen [Mass/volume] in Serum or Plasma21mg/dL6-21 mg/dLNormalS
2026-01-12Creatinine [Mass/volume] in Serum or Plasma1.2mg/dL0.59-1.04 mg/dLHighS
2026-01-12Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M54mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-01-12Glucose [Mass/volume] in Serum or Plasma92mg/dL70-99 mg/dLNormalS
2026-01-12Calcium [Mass/volume] in Serum or Plasma9.3mg/dL8.6-10.3 mg/dLNormalS
2026-01-12Phosphate [Mass/volume] in Serum or Plasma3.8mg/dL2.5-4.5 mg/dLNormalS
2026-01-12Parathyrin.intact [Mass/volume] in Serum or Plasma74pg/mL15-65 pg/mLHighS
2026-01-1225-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma21ng/mL30-100 ng/mLLowS
2026-01-12Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
2026-01-12Hemoglobin [Mass/volume] in Blood12.3g/dL12-15.5 g/dLNormalS
2026-01-12Cholesterol [Mass/volume] in Serum or Plasma214mg/dL<=199 mg/dLHighS
2026-01-12Cholesterol in HDL [Mass/volume] in Serum or Plasma54mg/dL>=50 mg/dLNormalS
2026-01-12Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation134mg/dL<=99 mg/dLHighS
2026-01-12Triglyceride [Mass/volume] in Serum or Plasma130mg/dL<=149 mg/dLNormalS
2026-01-12Hemoglobin A1c/Hemoglobin.total in Blood5.5%<=5.6%NormalS
2026-01-12Thyrotropin [Units/volume] in Serum or Plasma2.1m[IU]/L0.4-4 mIU/LNormalS
2026-01-12Albumin/Creatinine [Mass Ratio] in Urine240mg/g<=30 mg/gHighS
2026-01-12Erythrocytes [#/area] in Urine sediment by Microscopy high power field1/[HPF]<=2 /[HPF]NormalS
2026-01-12Kidney failure 2-year risk [Likelihood] by KFRE0.5%S
2026-01-12Kidney failure 5-year risk [Likelihood] by KFRE1.6%S
2026-01-12Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-01-12Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]5{score}S

Assessment

Plan of Treatment